Gray Market Retatrutide Shows Lower Weight Loss Than Clinical Trials, Preprint Study Finds
Source Summary
A preprint study found that people using gray market compounded retatrutide achieved less weight loss over up to 12 months compared to clinical trial participants. Retatrutide is an investigational triple hormone receptor agonist.
Why it matters
The finding demonstrates that gray market compounded versions of investigational drugs may deliver inferior clinical outcomes compared to regulated clinical trial formulations.
What remains uncertain
The study is a preprint and has not yet undergone peer review.
